- By ICR Secretariat
- Posted Monday, December 4, 2017
Bayer unblinds cancer drug study early to investigate patient deaths
- German drugmaker Bayer AG's efforts to expand use of its prostate cancer drug Xofigo hit a major safety setback Friday, after the company disclosed a Phase 3 study of the therapy would be unblinded early due to a higher number of patient deaths occurring in the treatment group than in the placebo arm.
- An independent data monitoring committee flagged the imbalance, recommending Bayer analyze the new findings from the study, which pairs Xofigo with J&J's Zytiga and prednisone to treat castration-resistant prostate cancer that has metastasized to bones.
- No patient in the Phase 3 trial is currently receiving Xofigo, as enrollment into the study completed in September 2016 and the drug is only administered for up to 6 doses over 24 weeks. Bayer said it had informed the relevant health regulators of the unblinding and plans to gather more detailed data on the new signal."
To read more, click here or follow the link above.